Cuckoo is an internet broadband provider. The company claims that incumbent internet providers treat customers with poor customer service, high prices, and complicated contracts. Cuckoo aims to change this by providing users with fair and transparent prices, simple contracts, high-quality routers, and responsive customer service. The company is currently developing its website and billing engine ahead of launching with its first customers in the second quarter of 2020. Cuckoo's business is in the pre-revenue stage. It expects to start generating revenue in May/June 2020 when they launch their broadband service. Cuckoo will use 50% of the investment towards paying salaries to staff, 25% as technology development fees, 10% as professional fees, 5% as rent, and 10% as AOB. Cuckoo's exit strategy is via a trade sale or listing in the United Kingdom.
days to go:
Expired
investment:
£69,622
Academy of Robotics is a company that specialises in combining artificial intelligence to create task simplifying machines. Its proprietary invention, Kar-Go, is one of the world’s first AI-controlled autonomous vehicles that aims to remove the need for human intervention in last-mile deliveries reducing labour costs by as much as 90%. Last-mile delivery is a £78 billion business, and e-commerce customers increasingly expect cheap and fast deliveries. This is where Kar-go aims to establish itself as the market leader. The company utilises 'Platform-as-a-service' business model where last-mile autonomous delivery is sold as a service that consists of sale or rental of vehicles & infrastructure, operators and maintenance services, and other verticals. For its innovation, Academy of Robotics has been cited by British business magnate Richard Branson & Virgin as one of the companies to make a serious impact in the autonomous car space. It has also been featured on TV and in over 200 publications including The BBC, Wired, Mail Online, Guardian amongst others. The company will use the investment to finance the building of 10 vehicles which will be used to facilitate on-road-trial.
days to go:
Expired
investment:
Withheld
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
The Best dot dot is a positive review website that lets individuals celebrate the good things in life and in turn, enables others to benefit from those experiences. The company aims to create a leading platform, with a large, engaged user base and ultimately to maximise shareholder value. The company has a full robust technology infrastructure and platform in place, consisting of a mix of unique in house technology and tried and tested industry-standard platforms. Significant work has already been done to create the IP that will be purchased by the company and the funds raised will be used to build on the work already done and to take the business to the next level. By increasing the user base, the revenue will rapidly increase as the company introduces additional revenue streams.
days to go:
Expired
investment:
£19,050
PopUp Painting (PUP) is an art company that aims to be the leader in organising experiential social painting events in the UK. The company endeavours to bring art out of the classroom and gallery into the places people meet on an everyday basis, thereby, unleashing creativity. PUP has hosted over 45,000 guests to date. Total revenues to date are £1.1 million. In the last financial year, the company generated revenues of £373,000. The COVID-19 pandemic in March led to PUP launching its online art sessions which was met with positive feedback. The company resumed hosting in-person COVID-secure events from July 2020 onwards. PUP is seeking £175,000 at a pre-money valuation of £1.3 million to launch its own Central London experiential events space and to expand its current services to reach a new product market.
days to go:
Expired
investment:
Withheld
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
Invluencer is a Venture Capital (VC) company with an economic model designed to bring VC to the masses. Invluencer believes in boosting greater investment capability between investors and company representatives. This is undertaken by creating a smart-contract enabled 'Intelligent Wallet' for autonomous investment in vetted high-growth companies facilitated by Invluencer’s unique Multi-Asset Platform (I-MAP) and Intelligent Distributed Due Diligence (i3D) platform. Through these platforms, the company aims to simplify investment and open liquidity between worthy companies and accredited investors. The company will use the investments to continue the development of due diligence and fund management platforms, strengthen the investment team and analysis team, strengthen relationships and partnerships within the VC ecosystem.
days to go:
Expired
investment:
£154,000
Elute Intelligence is an online platform that makes searching documents fast, simple, and accurate. The platform is optimised to handle a variety of tasks such as plagiarism detection, patent searching, fraud detection, governance and compliance, and e-discovery to name a few. Using a unique AI-based system, users can upload long-form documentation, and the system will analyse, tag, and find related articles across a wide range of academic journals and data sources. The company is looking to engage in partnerships: with government and commercial R&D teams to help accelerate research into Covid-19, with development partners to help expand the system into other research areas, and with investors interested in an AI and big data platform that can transform scientific research processes.
days to go:
Expired
investment:
Withheld
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.
days to go:
Expired
investment:
Withheld
